ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.344,88
0,30%
S&P 500
5.667,56
0,08%
US Dollar vs BRL
5,7351
1,05%
Bitcoin
84.011,39
-0,14%
Brent Oil
71,775
-0,13%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Nexalin Technologies Inc (NXLIW)

  7. Nexalin Technologies Inc (NXLIW) Notícias

NXLIW

Nexalin Technologies (NXLIW)

Nexalin Technologies Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NXLIW
DataHoraFonteTítuloCódigoCompanhia
14/03/202516:41Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NXLIWNexalin Technologies Inc
13/03/202517:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXLIWNexalin Technologies Inc
03/03/202510:30GlobeNewswire Inc.Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use DisordersNASDAQ:NXLIWNexalin Technologies Inc
28/02/202510:30GlobeNewswire Inc.Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB ApprovalNASDAQ:NXLIWNexalin Technologies Inc
26/02/202510:30GlobeNewswire Inc.Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory BoardNASDAQ:NXLIWNexalin Technologies Inc
18/02/202510:30GlobeNewswire Inc.Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD TreatmentNASDAQ:NXLIWNexalin Technologies Inc
10/02/202520:21Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:NXLIWNexalin Technologies Inc
10/02/202511:00GlobeNewswire Inc.Nexalin Appointed as Industry Co-Chair of National TBI Registry CoalitionNASDAQ:NXLIWNexalin Technologies Inc
06/02/202515:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXLIWNexalin Technologies Inc
04/02/202502:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NXLIWNexalin Technologies Inc
03/02/202510:30GlobeNewswire Inc.Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark StudyNASDAQ:NXLIWNexalin Technologies Inc
30/01/202519:15Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:NXLIWNexalin Technologies Inc
23/01/202513:00GlobeNewswire Inc.Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23NASDAQ:NXLIWNexalin Technologies Inc
14/01/202510:30GlobeNewswire Inc.Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025NASDAQ:NXLIWNexalin Technologies Inc
23/12/202412:00GlobeNewswire Inc.Nexalin Technology Completes Phase 1of its Innovative Virtual ClinicNASDAQ:NXLIWNexalin Technologies Inc
20/12/202414:35Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:NXLIWNexalin Technologies Inc
26/11/202412:00GlobeNewswire Inc.New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation MarketNASDAQ:NXLIWNexalin Technologies Inc
11/11/202410:00GlobeNewswire Inc.Nexalin Technology CEO Provides Letter to ShareholdersNASDAQ:NXLIWNexalin Technologies Inc
08/11/202418:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXLIWNexalin Technologies Inc
01/11/202415:00GlobeNewswire Inc.Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5thNASDAQ:NXLIWNexalin Technologies Inc
01/11/202411:34GlobeNewswire Inc.Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsNASDAQ:NXLIWNexalin Technologies Inc
28/10/202409:30GlobeNewswire Inc.Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's DiseaseNASDAQ:NXLIWNexalin Technologies Inc
22/10/202415:15GlobeNewswire Inc.Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VANASDAQ:NXLIWNexalin Technologies Inc
17/10/202409:30GlobeNewswire Inc.New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s PatientsNASDAQ:NXLIWNexalin Technologies Inc
14/10/202409:30GlobeNewswire Inc.Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory AffairsNASDAQ:NXLIWNexalin Technologies Inc
05/09/202410:00GlobeNewswire Inc.Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid TreatmentNASDAQ:NXLIWNexalin Technologies Inc
18/07/202409:30GlobeNewswire Inc.Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use RecoveryNASDAQ:NXLIWNexalin Technologies Inc
01/07/202415:45GlobeNewswire Inc.Nexalin Technology Announces Closing of $5.2 Million Public OfferingNASDAQ:NXLIWNexalin Technologies Inc
27/06/202422:15GlobeNewswire Inc.Nexalin Technology Announces Pricing of $5.2 Million Public OfferingNASDAQ:NXLIWNexalin Technologies Inc
26/06/202410:00GlobeNewswire Inc.Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific JournalNASDAQ:NXLIWNexalin Technologies Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NXLIW

Seu Histórico Recente

LSE
ELX
El Oro
TG
A3LTAC
AXA
AMEX
NVDX
T Rex 2X Long NVIDIA Dai...
NASDAQ
ACHV
Achieve Life Sciences
AMEX
XSHQ
Invesco S&P SmallCap Qua...
NASDAQ
ATRC
AtriCure
LSE
EXXI
NASDAQ
VRDN
Viridian Therapeutics
NASDAQ
ASRV
AmeriServ Financial
AMEX
ETHT
Proshares Ultra Ether ETF
USOTC
MUEL
Paul Meuller (PK)
NASDAQ
HAS
Hasbro
NASDAQ
IRBT
iRobot
NASDAQ
SNCR
Synchronoss Technologies
NYSE
BLDR
Builders FirstSource
NYSE
TMHC
Taylor Morrison Home
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios